Efficacy and safety of intravitreal aflibercept (Eylea®) therapy using a proactive treat-and-extend regimen in neovascular AMD

Article

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Download Supplement

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Related Content
From Optical to Digital Precision: Advancing Retinal Surgery with the ARTEVO 850 Microscope

From Optical to Digital Precision: Advancing Retinal Surgery with the ARTEVO 850 Microscope

Rodolfo Mastropasqua MD, PhD, FEBO
August 23rd 2025
Article
Site Logo

Updates From Angiogenesis-2022

August 23rd 2025
Podcast
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach

Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach

Joong Hun Kim, MD
August 23rd 2025
Article
Site Logo

Updates from ASRS 2021

August 23rd 2025
Podcast
Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy?

Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy?

August 23rd 2025
Article
Site Logo

Three-year outcomes of aflibercept 8mg in neovascular age related macular degeneration and diabetic macular edema

Sponsored by Bayer
August 23rd 2025
Article
© 2025 MJH Life Sciences

All rights reserved.